Skip to main content

Table 2 General haemodynamics in animals subjected to acute pulmonary hypertension

From: Effects of inhaled iloprost on right ventricular contractility, right ventriculo-vascular coupling and ventricular interdependence: a randomized placebo-controlled trial in an experimental model of acute pulmonary hypertension

Parameter

Treatment

Baseline

Pulmonary hypertension

   

Pre-inhalation

5 minutes after inhalation

HR (beats/minute)

Iloprost

88 ± 12

112 ± 13*

109 ± 7*

 

Control

90 ± 16

111 ± 14*

116 ± 15*

CO (l/minute)

Iloprost

4.5 ± 0.5

5.0 ± 0.4

5.6 ± 0.9

 

Control

4.1 ± 0.9

4.3 ± 0.6

3.9 ± 1.0

SV (ml)

Iloprost

53 ± 6

45 ± 6

51 ± 9

 

Control

45 ± 13

40 ± 10

35 ± 11

MAP (mmHg)

Iloprost

86 ± 18

69 ± 16*

74 ± 17*

 

Control

81 ± 7

70 ± 7*

70 ± 11*

LVEDP (mmHg)

Iloprost

11 ± 2

10 ± 2

11 ± 2

 

Control

11 ± 3

10 ± 3

11 ± 2

RVEDP (mmHg)

Iloprost

10 ± 1

11 ± 1

10 ± 2

 

Control

10 ± 2

12 ± 1

12 ± 1

SVR (dyn·s/cm5)

Iloprost

1,329 ± 324

952 ± 337*

971 ± 406*

 

Control

1,518 ± 344

1,087 ± 224*

1,257 ± 368*

PVR (dyn·s/cm5)

Iloprost

178 ± 79

366 ± 126*

193 ± 66†‡

 

Control

210 ± 105

448 ± 168*

464 ± 201*

PVR/SVR

Iloprost

0.14 ± 0.06

0.39 ± 0.07*

0.21 ± 0.09

 

Control

0.13 ± 0.05

0.41 ± 0.12*

0.37 ± 0.12*

  1. Values are shown for baseline and in pulmonary hypertension before inhalation and 5 minutes after inhalation of either iloprost or control. For the complete experimental time course, see Additional file 3. Values are expressed as mean ± standard deviation. *P < 0.05 versus baseline; P < 0.05 versus before inhalation; P < 0.05 iloprost versus control (corrected for multiple comparisons). CO, cardiac output; HR, heart rate; L(R)VEDP, left (right) ventricular end-diastolic pressure; MAP, mean arterial pressure; S(P)VR, systemic (pulmonary) vascular resistance; SV, stroke volume.